An analysis of drug costs for the management of chemotherapy-related side effects in advanced colorectal cancer: A comparison between raltitrexed ('tomudex') and 5-fluorouracil plus folinic acid

Journal of Oncology Pharmacy Practice

Volumn 2, Issue 3, 1996, Pages 186-190

  Elliott, Rachel ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adverse effects; Cost and cost analysis; Fluoroura cil; Raltitrexed; Tomudex

Indexed keywords

EID: 0001240520     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529600200309     Document Type: Article

References (19)

1. Estève J, Kricker A, Ferlay J,et al,eds. Facts and figures of cancer in the European Community. Lyon, France: International Agency for Research on Cancer; 1993.
2. Ross PJ, Cunningham D. Oncology: Chemotherapy of metastatic bowel cancer. Br J Hosp Med. 1996; 55:263-266.
3. Cunningham D., Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer. 1993;29A:2077-2079.
4. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol. 1992;10: 904-911.
5. Scheithauer W., Rosen H., Komek G-V.,et al.Randomised comparison of combination chemotherapy plus supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306:752-755.
6. Cunningham D., Zalcberg JR, Rath U.,et al."Tomudex" (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer. 1995;31A:1945-1954.
7. Seitz JF, Cunningham D., Rath U.,et al.Final results and survival data of a large randomised trial of "Tomudex" in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5-FU + LV) [Abstract]. Proc Am Soc Clin Oncol. 1996;15:201.
8. Kerr D. "Tomudex" (ZD1694), a new direct and specific thymidylate synthase inhibitor, has resource saving implications in the management of colorectal cancer. Qual Life Res. 1995;4:576.
9. Leese B. The costs of treating febrile neutropenia in six U.K. hospitals. Eur J Cancer. 1993;29A(suppl 7): S15-18.
10. Leese B., Collin R., Clark DJ The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics. 1994;6:233-239.
11. Montero MC, Valdivia ML, Carvajal E.,et al.Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci. 1994;16:187-191.
12. Dranitsaris G., Tran TM Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer. 1995;31A:2174 -2180.
13. Cunningham D., Gore M., Davidson N.,et al.The real cost of emesis-an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer. 1993;29A:303-306.
14. O'Brien BJ, Rusthoven J., Rocchi A.,et al.Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. Can Med Assoc J. 1993;149: 296-301.
15. Johnson NE, Shoheiber O., Nash DB The costs of treating toxicities in cancer chemotherapy patients [Abstract]. Proc Am Soc Clin Oncol. 1995;14:524.
16. Summerhayes M. Cost and pharmacy workload implications of "Tomudex" treatment. Inpharma. 1996;Suppl 2:10-11.
17. Poon MA, O'Connell MJ, Wieand HS,et al.Biochemical modulation of fluorouracil with folinic acid: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991;9:1967-1972.
18. Buroker TR, O'Connell MJ, Wieand HS,et al.Randomized comparison of two schedules of fluorouracil and folinic acid in the treatment of advanced colorectal cancer. J Clin Oncol. 1994;12:14-20.
19. Lokich JJ, Ahlgren JD, Gullo JJ,et al.A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus administration schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989;7:425- 432.